Back

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry

29 August 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Lipids: drug therapy Drug therapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

4 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor C. Soh (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Doctor T. Wang (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Doctor M. Bellomare (Milan, IT)
Abstract Slides Video

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Lipids: drug therapy

The Event

Event poster

ESC Congress 2025

29 August 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors
thumbnail
Congress Presentation
Optimizing lipid control after acute coronary syndrome: can we strike early and strong in real-world practice?
thumbnail
Congress Presentation
Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources